Safety and Immunogenicity of Meningococcal Conjugate Vaccine in Healthy Adults Aged 19 to 55 Years Old

NCT04714229 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Infection, Meningococcal

Interventions

BIOLOGICAL: Meningococcal(Groups A, C, W-135, and Y) Conjugate Vaccine
BIOLOGICAL: Meningococcal(Groups A, C, Y, and W-135) Conjugate Vaccine

Sponsor

EuBiologics Co.,Ltd